Apellis Pharmaceuticals Inc
NEWS
Biopharma and life sciences companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.
It was a busy week for clinical trial announcements. Here’s a look.
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.
It was another busy week for clinical trial news. Here’s a look.
Patients and patient organizations, which have detailed insights in the natural history of a rare disease, should be integral, too.
It was a busy week for clinical trial news. Here’s a look.
Apellis Pharmaceuticals reported topline results from its Phase III DERBY and OAKS clinical trials for geographic atrophy secondary to age-related macular degeneration.
venBio Global Strategic Fund IV will invest primarily in drug companies focused on developing therapies for unmet medical needs.
Empaveli (pegcetacoplan) is the first and only targeted C3 therapy for the treatment of adults with PNH, the Waltham, Mass.-based company said in its announcement.
JOBS
IN THE PRESS